<DOC>
	<DOCNO>NCT01549171</DOCNO>
	<brief_summary>Human fallopian tube secretes high concentration prostacyclin . Fallopian tube site early embryo development . The effect prostacyclin human early embryo development wait clarify . The study hypothesis prostacyclin enhance early embryo development .</brief_summary>
	<brief_title>Enhanced Assisted Reproductive Technology Pregnancy Rate Prostacyclin Analog ( Iloprost )</brief_title>
	<detailed_description>Huang et al , find human fallopian tube express prostacyclin synthetase cyclooxygenase . These enzyme system synthesize abundant prostacyclin ( PGI2 ) . In fallopian tube PGI2 cause smooth muscle relaxation , possibly facilitate tubal transport gamete embryos . Huang et al report addition PGI2 analogue Iloprost embryo culture medium significantly enhance mouse embryo development blastocyst complete hatch stage . The implantation live birth rate Iloprost culture embryos significantly well non-Iloprost embryo mouse model . The mean weight fetal mouse significant different control group . There teratogenic effect observe . In previously present study , investigator culture donated frozen human zygotes culture medium without addition Iloprost . The Iloprost treat embryo show significantly good growth rate morphology , determine size , grade trophectoderm inner cell mass . Iloprost FDA approve treatment pulmonary hypertension . It significantly longer half-life native PGI2 . Iloprost class C pregnancy drug associate teratogenic effect . This study intend expand usage Iloprost culture embryo .</detailed_description>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<criteria>ART case age &lt; 40 preimplantation genetic diagnosis procedure</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Human ART</keyword>
	<keyword>Prostacyclin</keyword>
	<keyword>Iloprost</keyword>
	<keyword>Pregnancy</keyword>
</DOC>